# Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Source: https://onco.cc/trials/nct04410796/  
OnCo record `nct04410796` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of osimertinib, carboplatin and pemetrexed in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.

## Summary

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers is a phase 2, randomised interventional study registered as NCT04410796 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 571 participants, started 2020-05-28 and due to reach its primary completion in 2027-05. Interventions recorded: Osimertinib; Carboplatin; Pemetrexed. Conditions listed: Metastatic Non-small Cell Lung Cancer. Primary outcome: Determine the progression-free survival. Lung eligibility wording from the registry: "* Biopsy proven metastatic non-small cell lung cancer, confirmed at enrolling institution". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04410796
- Phase: 2
- Setting: A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 571

## Sources

- ClinicalTrials.gov NCT04410796: https://clinicaltrials.gov/study/NCT04410796

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Guardant Health](https://onco.cc/companies/guardant-health/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04410796.json